SI0832104T1 - Dolastatin derivatives, their preparation and use - Google Patents

Dolastatin derivatives, their preparation and use

Info

Publication number
SI0832104T1
SI0832104T1 SI9630539T SI9630539T SI0832104T1 SI 0832104 T1 SI0832104 T1 SI 0832104T1 SI 9630539 T SI9630539 T SI 9630539T SI 9630539 T SI9630539 T SI 9630539T SI 0832104 T1 SI0832104 T1 SI 0832104T1
Authority
SI
Slovenia
Prior art keywords
preparation
dolastatin derivatives
dolastatin
derivatives
Prior art date
Application number
SI9630539T
Other languages
English (en)
Slovenian (sl)
Inventor
Andreas Haupt
Franz Emling
Cynthia A. Romerdahl
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of SI0832104T1 publication Critical patent/SI0832104T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI9630539T 1995-06-07 1996-06-03 Dolastatin derivatives, their preparation and use SI0832104T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
EP96918660A EP0832104B1 (fr) 1995-06-07 1996-06-03 Derives de la dolastatine, leurs preparation et leurs utilisation
PCT/EP1996/002392 WO1996040751A1 (fr) 1995-06-07 1996-06-03 Nouveaux derives de dolastatine, leur preparation et leur utilisation

Publications (1)

Publication Number Publication Date
SI0832104T1 true SI0832104T1 (en) 2003-08-31

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9630539T SI0832104T1 (en) 1995-06-07 1996-06-03 Dolastatin derivatives, their preparation and use
SI9630550T SI0871656T1 (en) 1995-06-07 1996-06-03 Dolastatin derivatives, their preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI9630550T SI0871656T1 (en) 1995-06-07 1996-06-03 Dolastatin derivatives, their preparation and use

Country Status (33)

Country Link
US (1) US5831002A (fr)
EP (2) EP0832104B1 (fr)
JP (2) JP4221062B2 (fr)
KR (2) KR100437986B1 (fr)
CN (2) CN1182153C (fr)
AR (2) AR003427A1 (fr)
AT (2) ATE223431T1 (fr)
AU (2) AU725170B2 (fr)
BG (2) BG102125A (fr)
BR (2) BR9609424A (fr)
CA (2) CA2219818C (fr)
CO (2) CO4700527A1 (fr)
CZ (2) CZ293682B6 (fr)
DE (2) DE69623992T2 (fr)
DK (2) DK0871656T3 (fr)
ES (2) ES2188759T3 (fr)
HR (2) HRP960277A2 (fr)
HU (2) HU228073B1 (fr)
IL (2) IL122216A (fr)
MX (2) MX9709147A (fr)
MY (2) MY119042A (fr)
NO (2) NO318384B1 (fr)
NZ (2) NZ310444A (fr)
PL (2) PL185762B1 (fr)
PT (2) PT871656E (fr)
RO (2) RO119783B1 (fr)
SI (2) SI0832104T1 (fr)
SK (1) SK282466B6 (fr)
TR (2) TR199701545T1 (fr)
TW (2) TW508357B (fr)
UA (2) UA46775C2 (fr)
WO (2) WO1996040752A1 (fr)
ZA (2) ZA964711B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2000051998A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
WO2002088298A1 (fr) 2001-04-27 2002-11-07 The Procter & Gamble Company Composes, compositions et procedes permettant de reguler des films biologiques
WO2003051835A2 (fr) * 2001-12-18 2003-06-26 Proteologics, Inc. Methodes et compositions d'inhibition de la production virale
US20050171014A1 (en) * 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
US8568637B2 (en) 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
EP1883627B1 (fr) 2005-05-18 2018-04-18 Pharmascience Inc. Composes liants de domaine bir
EP1924245A2 (fr) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Formulations topiques d'inhibiteurs d'histone desacetylase et procedes d'utilisation de celles-ci
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
AU2008239730B2 (en) 2007-04-12 2011-10-06 Scinopharm Taiwan, Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
BR112013030372A2 (pt) * 2011-05-27 2016-08-30 Ambrx Inc composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat
KR100286242B1 (ko) * 1992-05-20 2001-04-16 스타르크, 카르크 돌라스타틴 유도체
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
RO119783B1 (ro) 2005-03-30
CN1182154C (zh) 2004-12-29
PT832104E (pt) 2002-12-31
CZ376597A3 (cs) 1998-06-17
ES2188759T3 (es) 2003-07-01
NO975710L (no) 1998-02-02
NO975710D0 (no) 1997-12-05
CA2219819C (fr) 2008-05-20
AU6124196A (en) 1996-12-30
MY119042A (en) 2005-03-31
PT871656E (pt) 2002-12-31
NZ310444A (en) 1999-11-29
HUP9801910A3 (en) 1999-06-28
CN1182153C (zh) 2004-12-29
CA2219818A1 (fr) 1996-12-19
HRP960257A2 (en) 1998-02-28
NZ310443A (en) 1999-10-28
BG102152A (en) 1998-09-30
HU228073B1 (hu) 2012-09-28
DK0871656T3 (da) 2003-01-27
DE69623472T2 (de) 2003-08-21
HRP960277A2 (en) 1997-10-31
EP0871656B1 (fr) 2002-09-25
EP0832104B1 (fr) 2002-09-04
NO975711L (no) 1998-01-30
ATE223431T1 (de) 2002-09-15
RO118953B1 (ro) 2004-01-30
JP3957751B2 (ja) 2007-08-15
HUP9801817A3 (en) 1999-06-28
MX9709147A (es) 1998-03-31
KR100437986B1 (ko) 2004-09-18
ES2186783T3 (es) 2003-05-16
WO1996040752A1 (fr) 1996-12-19
SK165397A3 (en) 1998-10-07
AU6124296A (en) 1996-12-30
CZ376397A3 (cs) 1998-06-17
MX9709146A (es) 1998-03-31
EP0832104A1 (fr) 1998-04-01
AU725164B2 (en) 2000-10-05
CA2219819A1 (fr) 1996-12-19
CO4700526A1 (es) 1998-12-29
IL122215A0 (en) 1998-04-05
UA46776C2 (uk) 2002-06-17
ZA964711B (en) 1997-12-08
CN1187199A (zh) 1998-07-08
IL122216A (en) 2002-02-10
CA2219818C (fr) 2008-05-20
TW424096B (en) 2001-03-01
ZA964710B (en) 1997-12-08
BR9609424A (pt) 2000-03-28
JP4221062B2 (ja) 2009-02-12
KR19990022583A (ko) 1999-03-25
PL185762B1 (pl) 2003-07-31
UA46775C2 (uk) 2002-06-17
BR9609423A (pt) 1999-06-29
SI0871656T1 (en) 2003-08-31
AR003136A1 (es) 1998-07-08
AR003427A1 (es) 1998-08-05
ATE224910T1 (de) 2002-10-15
PL185763B1 (pl) 2003-07-31
MY124487A (en) 2006-06-30
CN1187198A (zh) 1998-07-08
SK282466B6 (sk) 2002-02-05
TW508357B (en) 2002-11-01
DE69623992T2 (de) 2003-05-22
IL122216A0 (en) 1998-04-05
US5831002A (en) 1998-11-03
CZ293683B6 (cs) 2004-07-14
JPH11504653A (ja) 1999-04-27
DE69623472D1 (de) 2002-10-10
KR19990022582A (ko) 1999-03-25
EP0871656A1 (fr) 1998-10-21
HU228071B1 (hu) 2012-09-28
JPH11504652A (ja) 1999-04-27
NO317670B1 (no) 2004-11-29
WO1996040751A1 (fr) 1996-12-19
CZ293682B6 (cs) 2004-07-14
PL323723A1 (en) 1998-04-14
PL323726A1 (en) 1998-04-14
BG102125A (en) 1998-09-30
TR199701545T1 (xx) 1998-04-21
CO4700527A1 (es) 1998-12-29
AU725170B2 (en) 2000-10-05
KR100437985B1 (ko) 2004-09-18
IL122215A (en) 2001-08-26
NO975711D0 (no) 1997-12-05
DK0832104T3 (da) 2003-01-06
HUP9801910A2 (hu) 1999-01-28
TR199701544T1 (xx) 1998-03-21
NO318384B1 (no) 2005-03-14
DE69623992D1 (de) 2002-10-31
HUP9801817A2 (hu) 1998-11-30

Similar Documents

Publication Publication Date Title
HUP9801910A3 (en) Dolastatin derivatives, their preparation and use
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
EP0728749A3 (fr) Dérivés de triazine, leur préparation et leur application
EP0710667B8 (fr) Oligonucléotides modifiés, leur préparation et leur utilisation
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
HUP9801139A3 (en) Polysiloxane-polyol macromers, their preparation and their use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL114795A0 (en) N-benzylindole- and benmzopyrazole derivatives their preparation and use
SI1019358T1 (en) 3,3-diarylpropylamines , their use and preparation
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IL117807A0 (en) 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives their preparation and use
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
AU7095296A (en) Phosphorylamides, their preparation and use
IL118443A0 (en) Cycloalkane-benzylidene derivatives their preparation and use
HK1014938A1 (en) Oxazolidinone derivatives, their preparation and therapeutical use
IL116710A0 (en) Substituted 2-phenylpyridines their preparation and use
IL116712A0 (en) Substituted 2-phenylpyridines their preparation and use
SG49960A1 (en) Dyes, processes for their preparation and their use
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
IL116711A0 (en) Substituted 2-phenylpyridines their preparation and use
EP0744125A3 (fr) Complexe d'iode et son application
IL122686A0 (en) Benzylhydroxylamines their preparation and use
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use